In myeloma clinical setting, CD34 + stem cells with minimal contamination from clonotypic cells are used in hematopoietic stem cell transplantation as it is believed that myeloma cells lack CD34 [52]. This evidence concerns the gene CD34 and plasma cell myeloma.